Hikal Crescita futura
Criteri Future verificati 4/6
Si prevede che Hikal aumenterà gli utili e i ricavi rispettivamente del 135.3% e 12.2% all'anno, mentre si prevede che l'EPS crescerà del 135.6% all'anno.
Informazioni chiave
135.3%
Tasso di crescita degli utili
135.58%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 17.7% |
| Tasso di crescita dei ricavi | 12.2% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 06 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Jun 22
524735: Dividend And Board Changes Will Support Future Upside Potential
Analysts have trimmed their price target for Hikal from ₹320 to ₹300, reflecting updated assumptions for slightly lower revenue growth, a softer profit margin outlook, and a higher future P/E multiple. What’s in the News for Hikal Hikal has scheduled a Special or Extraordinary Shareholders Meeting on July 4, 2026, to be conducted via postal ballot in India.Aggiornamento narrativa • Jun 04
524735: Board Actions And Dividend Decision Will Support Future Upside Potential
Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.Aggiornamento narrativa • Apr 26
524735: Interim Dividend And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320, reflecting unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend on equity shares for FY 2025-26 (company filing).Aggiornamento narrativa • Apr 12
524735: Interim Dividend And Steady Assumptions Will Support Bullish Upside Potential
Analysts have maintained their fair value estimate for Hikal at ₹320, citing essentially unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E. This keeps their overall price target view steady.Aggiornamento narrativa • Mar 28
524735: Interim Dividend And Stable Assumptions Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal broadly unchanged at around ₹320, reflecting largely steady assumptions on discount rate, revenue growth, profit margin and future P/E, and signaling no meaningful shift in their overall view of the stock. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento narrativa • Mar 13
524735: Interim Dividend And Stable Outlook Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320. This points to largely unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiple in their latest price target update.Aggiornamento narrativa • Feb 26
524735: Interim Dividend And Upcoming Results Will Support Bullish Upside Potential
Analysts have kept their price target on Hikal unchanged at ₹320, reflecting broadly steady views on revenue growth, margins and fair value, with only a small adjustment to the assumed future P/E multiple. What's in the News The Board will meet on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend for FY 2025-26 (company filing).Aggiornamento narrativa • Feb 12
524735: Upcoming Results And Interim Dividend Decision Will Support Future Upside
Analysts have lifted their price target on Hikal to ₹320, reflecting updated assumptions around a lower discount rate, faster revenue growth, a slimmer profit margin, and a higher future P/E multiple. What's in the News Board meeting scheduled on Feb 11, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Aggiornamento narrativa • Jan 05
524735: Stable Margins And Upcoming Results Will Support Future Dividend Upside
Analysts have kept their fair value estimate for Hikal steady at ₹320.0 per share. This reflects unchanged views on growth, margins, discount rate, and future P/E assumptions used in their price target work.Aggiornamento narrativa • Dec 15
524735: Profitability Will Improve As Stable Margins Support Future Dividend Upside
Analysts have modestly reiterated their outlook on Hikal, keeping the average 12 month price target broadly stable around ₹320 per share, as unchanged growth, margin, and valuation assumptions continue to support a steady fair value profile. What's in the News Board meeting scheduled for November 13, 2025, to review and approve standalone and consolidated unaudited financial results for Q2 and H1 FY2025 (company filing) Shareholders at the 37th AGM on September 23, 2025, approved a final dividend of INR 0.80 per equity share of INR 2, taking the total FY2024-25 dividend to INR 1.40 per share (AGM resolution) Valuation Changes Fair Value: Unchanged at approximately ₹320 per share, indicating a stable assessment of intrinsic value.Aggiornamento narrativa • Nov 30
524735: Profitability Will Improve As Margins Recover And Regulatory Risks Fade
Analysts have raised their price target for Hikal to ₹320.00, citing improved forecasts for revenue growth and profit margin in addition to a stronger outlook for future profitability. What's in the News A board meeting is scheduled for November 13, 2025, to approve unaudited financial results for the second quarter and half year ended September 30, 2025 (Key Developments).Aggiornamento narrativa • Nov 15
524735: Future Margins Will Recover Following Regulatory Facility Improvements
Narrative Update: Hikal Analyst Price Target Adjustment Analysts have decreased their fair value estimate for Hikal from ₹390 to ₹320 due to revised expectations for revenue decline and lower profit margins. What's in the News The United States FDA issued a warning letter to Hikal's drug manufacturing facility in Karnataka following an inspection in February 2025.Aggiornamento narrativa • Sep 05
Global Supply Chain Diversification Will Unlock Indian CRAMS Potential
As both net profit margin and consensus revenue growth forecasts for Hikal remained stable, analysts have maintained their fair value estimate with the price target unchanged at ₹390.00. What's in the News Hikal's Board of Directors will meet to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2025.
Nuova narrativa • Feb 09
New Panoli Facility And Global Expansions Will Strengthen Operations Over Next 2-3 Years
Strategic focus on operating leverage and product mix is set to improve net margins and revenue diversification.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2028 | 21,429 | 1,110 | 1,431 | N/A | 1 |
| 3/31/2027 | 18,831 | 373 | 486 | N/A | 1 |
| 6/30/2026 | 17,350 | -338 | N/A | N/A | N/A |
| 3/31/2026 | 17,126 | -488 | 1,539 | 3,020 | N/A |
| 12/31/2025 | 17,456 | -130 | N/A | N/A | N/A |
| 9/30/2025 | 16,990 | 101 | 1,625 | 3,049 | N/A |
| 6/30/2025 | 18,334 | 633 | N/A | N/A | N/A |
| 3/31/2025 | 18,598 | 908 | 1,431 | 2,804 | N/A |
| 12/31/2024 | 18,215 | 746 | N/A | N/A | N/A |
| 9/30/2024 | 18,214 | 736 | 1,054 | 2,526 | N/A |
| 6/30/2024 | 18,034 | 678 | N/A | N/A | N/A |
| 3/31/2024 | 17,846 | 696 | -175 | 1,867 | N/A |
| 12/31/2023 | 18,158 | 716 | N/A | N/A | N/A |
| 9/30/2023 | 19,084 | 819 | 684 | 3,396 | N/A |
| 6/30/2023 | 20,323 | 942 | N/A | N/A | N/A |
| 3/31/2023 | 20,230 | 784 | 127 | 3,153 | N/A |
| 12/31/2022 | 19,801 | 631 | N/A | N/A | N/A |
| 9/30/2022 | 19,544 | 819 | -891 | 1,935 | N/A |
| 6/30/2022 | 18,647 | 1,011 | N/A | N/A | N/A |
| 3/31/2022 | 19,427 | 1,605 | 204 | 2,937 | N/A |
| 12/31/2021 | 19,728 | 1,907 | N/A | N/A | N/A |
| 9/30/2021 | 19,216 | 1,858 | 1,103 | 3,413 | N/A |
| 6/30/2021 | 18,245 | 1,687 | N/A | N/A | N/A |
| 3/31/2021 | 17,204 | 1,331 | 714 | 2,290 | N/A |
| 12/31/2020 | 15,670 | 1,067 | N/A | N/A | N/A |
| 9/30/2020 | 15,077 | 948 | 1,051 | 2,304 | N/A |
| 6/30/2020 | 14,569 | 742 | N/A | N/A | N/A |
| 3/31/2020 | 15,073 | 844 | N/A | 2,849 | N/A |
| 12/31/2019 | 15,858 | 933 | N/A | N/A | N/A |
| 9/30/2019 | 15,934 | 943 | N/A | 2,203 | N/A |
| 6/30/2019 | 16,672 | 1,124 | N/A | N/A | N/A |
| 3/31/2019 | 15,896 | 1,031 | N/A | 1,856 | N/A |
| 3/31/2018 | 12,961 | 772 | N/A | 1,388 | N/A |
| 3/31/2017 | 10,139 | 677 | N/A | 1,635 | N/A |
| 3/31/2016 | 9,245 | 412 | N/A | 1,856 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che 524735 diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 6.9% ).
Guadagni vs Mercato: Si prevede che 524735 diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede 524735 diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di 524735 ( 12.2% all'anno) crescerà più rapidamente del mercato Indian ( 11% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di 524735 ( 12.2% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di 524735 è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/12 13:38 |
| Prezzo dell'azione a fine giornata | 2026/08/12 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Hikal Limited è coperta da 2 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Kameswari V. S. Chavali | FirstCall Research |